Quantcast

Subscribe to:
POZ magazine
Newsletters
Join POZ: Facebook MySpace Twitter Pinterest
Tumblr Google+ Flickr Instagram
POZ Personals
Sign In / Join
Username:
Password:
Welcome, Guest. Please login or register.
December 18, 2014, 06:59:12 AM

Login with username, password and session length


Members
Stats
  • Total Posts: 649720
  • Total Topics: 49588
  • Online Today: 149
  • Online Ever: 585
  • (January 07, 2014, 02:31:47 PM)
Users Online
Users: 6
Guests: 115
Total: 121

Welcome


Welcome to the POZ/AIDSmeds Community Forums, a round-the-clock discussion area for people with HIV/AIDS, their friends/family/caregivers, and others concerned about HIV/AIDS.  Click on the links below to browse our various forums; scroll down for a glance at the most recent posts; or join in the conversation yourself by registering on the left side of this page.

Privacy Warning:  Please realize that these forums are open to all, and are fully searchable via Google and other search engines. If you are HIV positive and disclose this in our forums, then it is almost the same thing as telling the whole world (or at least the World Wide Web). If this concerns you, then do not use a username or avatar that are self-identifying in any way. We do not allow the deletion of anything you post in these forums, so think before you post.

  • The information shared in these forums, by moderators and members, is designed to complement, not replace, the relationship between an individual and his/her own physician.

  • All members of these forums are, by default, not considered to be licensed medical providers. If otherwise, users must clearly define themselves as such.

  • Forums members must behave at all times with respect and honesty. Posting guidelines, including time-out and banning policies, have been established by the moderators of these forums. Click here for “Am I Infected?” posting guidelines. Click here for posting guidelines pertaining to all other POZ/AIDSmeds community forums.

  • We ask all forums members to provide references for health/medical/scientific information they provide, when it is not a personal experience being discussed. Please provide hyperlinks with full URLs or full citations of published works not available via the Internet. Additionally, all forums members must post information which are true and correct to their knowledge.

  • Product advertisement—including links; banners; editorial content; and clinical trial, study or survey participation—is strictly prohibited by forums members unless permission has been secured from POZ.

To change forums navigation language settings, click here (members only), Register now

Para cambiar sus preferencias de los foros en español, haz clic aquí (sólo miembros), Regístrate ahora

Finished Reading This? You can collapse this or any other box on this page by clicking the symbol in each box.

Author Topic: Vaccine for top opportunistic infection in HIV patients aims for trials in 2013  (Read 1194 times)

0 Members and 1 Guest are viewing this topic.

Offline ichigo_kun

  • Member
  • Posts: 49
A promising vaccine for the most common serious infection in people with HIV could reach clinical trials next year if it can attract $2.5 million to $3 million in investments this year.

MiniVax Inc.’s lead product is MVX-504, a vaccine to prevent the fungal infection Pneumocystis pneumonia (PCP), which often develops in the lungs of people with compromised immune systems like HIV/AIDS patients, cancer patients undergoing chemotherapy and organ transplant recipients. It causes pneumonia, fever and respiratory symptoms, and if not treated effectively, can be fatal.

The vaccine uses the antigen “mini-kexin,” part of a protein derived from Pneumocystis, to stimulate an anti-PCP immune response. A secondary product, MVX-505, is being developed as a therapeutic antibody to treat immunocompromised individuals who are already suffering from PCP.



Advertisement
With promising results in early stage studies, MiniVax plans to take its vaccine into clinical trials mid- to late next year, according to CEO A. Ray Chaudhuri. He said the company expects to find out within the next month whether the U.S. Food and Drug Administration will grant orphan drug status to the therapeutic antibody, which will allow an expedited approval path. If it receives orphan drug status, it will run on about the same time line as the vaccine, Chaudhuri said. If not, it will run a few quarters behind.
Currently, the standard of treatment for preventing and treating PCP is trimethoprim/sulfamethoxazole (TMP/SMX), a combination oral antibiotic drug sold under the names Bactrim (Roche), Septra (Monarch Pharmaceuticals) and various generics. It’s inexpensive and thought to be generally effective, but at least one-third of people who take it have an allergic reaction in the form of a skin rash or fever, or develop digestive side effects. Drug resistance with TMP/SMX is also a growing concern.

“Even though there’s competition in this market, there’s no one doing the vaccine for PCP that I’m aware of,” Chaudhuri said. “We’re trying to position it as a product that’s cheaper and more effective in preventing the infection.”

If the vaccine succeeds in trials, it would initially tap into a market comprising 1.1 million Americans with HIV/AIDS (and, eventually, 33 million people across the world). But there’s at least one problem that would remain unsolved: PCP is common in people who do not know they are infected with HIV.

Founded in 2011 with a $600,000 Small Business Innovative Research grant from the National Institutes of Health, MiniVax is now on the hunt for investors and pharmaceutical partners. Chaudhuri estimated the company would need $2.5 million to $3 million to push the vaccine through clinical trials and another $10 million to $12 million over the next two to three years to advance the therapeutic and another bacterial vaccine candidate against the hospital-acquired infection Klebsiella pneumoniae.

MiniVax is a spinout of Louisiana State University Health and Sciences Center, and is housed at the New Orleans BioInnovation Center.
http://www.medcitynews.com/2012/04/vaccine-for-top-opportunistic-infection-in-hiv-patients-aims-for-trials-in-2013/?utm_source=rss&utm_medium=rss&utm_campaign=vaccine-for-top-opportunistic-infection-in-hiv-patients-aims-for-trials-in-2013

 


Terms of Membership for these forums
 

© 2014 Smart + Strong. All Rights Reserved.   terms of use and your privacy
Smart + Strong® is a registered trademark of CDM Publishing, LLC.